Use of selective serotonin reuptake inhibitors and sleep quality: A population-based study

Journal of Clinical Sleep Medicine

Volumn 12, Issue 7, 2016, Pages 989-995

  Aarts, Nikkie ^a,b   Zuurbier, Lisette A ^b   Noordam, Raymond ^a,b   Hofman, Albert ^b   Tiemeier, Henning ^a,b   Stricker, Bruno H ^a,b,c   Visser, Loes E ^a,b,d  

^a Department of Internal Medicine ^*  (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Netherlands Health Care Inspectorate   (Netherlands)

^d Apotheek Haagse Ziekenhuizen   (Netherlands)

Author keywords

Antidepressive agents; Population surveillance; Questionnaires; Sleep

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AGED; ARTICLE; COHORT ANALYSIS; DEPRESSION; FEMALE; HUMAN; MALE; MEDICAL RECORD; PITTSBURGH SLEEP QUALITY INDEX; PROSPECTIVE STUDY; SLEEP PARAMETERS; SLEEP QUALITY; SLEEP TIME; DRUG EFFECTS; METHODOLOGY; SLEEP; SLEEP DISORDER;

AGED; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; RESEARCH DESIGN; SEROTONIN UPTAKE INHIBITORS; SLEEP; SLEEP WAKE DISORDERS;

EID: 84980041335     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.5932     Document Type: Article

References (37)

1. Thase ME, Kupfer DJ, Fasiczka AJ, Buysse DJ, Simons AD, Frank E. Identifying an abnormal electroencephalographic sleep profle to characterize major depressive disorder. Biol Psychiatry 1997;41:964-73.
2. Tsuno N, Besset A, Ritchie K. Sleep and depression. J Clin Psychiatry 2005;66:1254-69.
3. Argyropoulos SV, Wilson SJ. Sleep disturbances in depression and the effects of antidepressants. Int Rev Psychiatry 2005;17:237-45.
4. Thase ME. Depression and sleep: pathophysiology and treatment. Dialogues Clin Neurosci 2006;8:217-26.
5. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989;262:1479-84.
6. Almeida O P, Pfaff JJ. Sleep complaints among older general practice patients: association with depression. Br J Gen Pract 2005;55:864-6.
7. Jaussent I, Bouyer J, Ancelin ML et al. Insomnia and daytime sleepiness are risk factors for depressive symptoms in the elderly. Sleep 2011;34:1103-10.
8. Lee E, Cho HJ, Olmstead R, Levin MJ, Oxman MN, Irwin MR. Persistent sleep disturbance: a risk factor for recurrent depression in community-dwelling older adults. Sleep 2013;36:1685-91.
9. Oberndorfer S, Saletu-Zyhlarz G, Saletu B. Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality. Neuropsychobiology 2000;42:69-81.
10. Winokur A, Gary KA, Rodner S, Rae-Red C, Fernando AT, Szuba MP. Depression, sleep physiology, and antidepressant drugs. Depress Anxiety 2001;14:19-28.
11. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005;65:927-47.
12. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005;20:533-59.
13. DeMartinis NA, Winokur A. Effects of psychiatric medications on sleep and sleep disorders. CNS Neurol Disord Drug Targets 2007;6:17-29.
14. Mendels J, Kiev A, Fabre LF. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depress Anxiety 1999;9:54-60.
15. Beasley CM Jr, Sayler ME, Weiss AM, Potvin JH. Fluoxetine: activating and sedating effects at multiple fxed doses. J Clin Psychopharmacol 1992;12:328-33.
16. Gursky JT, Krahn LE. The effects of antidepressants on sleep: a review. Harv Rev Psychiatry 2000;8:298-306.
17. Saletu B, Frey R, Krupka M, Anderer P, Grunberger J, See WR. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fuoxetine on human sleep and awakening qualities. Sleep 1991;14:439-47.
18. Vasar V, Appelberg B, Rimon R, Selvaratnam J. The effect of fuoxetine on sleep: a longitudinal, double-blind polysomnographic study of healthy volunteers. Int Clin Psychopharmacol 1994;9:203-6.
19. Ridout F, Meadows R, Johnsen S, Hindmarch I. A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hum Psychopharmacol 2003;18:261-9.
20. Wilson SJ, Bailey JE, Alford C, Nutt DJ. Sleep and daytime sleepiness the next day following single night-time dose of fuvoxamine, dothiepin and placebo in normal volunteers. J Psychopharmacol 2000;14:378-86.
21. Ensrud KE, Joffe H, Guthrie KA, et al. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot fashes: a randomized controlled trial. Menopause 2012;19:848-55.
22. Zisapel N, Laudon M. Subjective assessment of the effects of CNS-active drugs on sleep by the Leeds sleep evaluation questionnaire: a review. Hum Psychopharmacol 2003;18:1-20.
23. Clark MS, Smith PO, Jamieson B. FPIN's clinical inquiries: antidepressants for the treatment of insomnia in patients with depression. Am Fam Physician 2011;84:1-2.
24. Hofman A, Grobbee DE, De Jong PTVM, Van den Ouweland FA. Determinants of disease and disability in the elderly: The Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403-22.
25. Hofman A, Murad S, Duijn C et al. The Rotterdam Study: 2014 objectives and design update. Eur J Epidemiol 2013;28:889-926.
26. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
27. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
28. World Health Organization. ATC/DDD Index 2014. World Health Organization Collaborating Centre for Drug Statistics Methodology Oslo, Norway. Accessed September 2013. Available from: http://www.whocc.no/atc-ddd-index.
29. United Nations Educational, Scientifc and Cultural Organization (UNESCO). International Standard Classifcation of Education (ISCED), 1976. Available from: http://unesdoc.unesco.org/images/0002/000209/020992eb.pdf
30. van Rossum CTM. Socioeconomic Inequalities in Cardiovascular Disease in an Ageing Population [Thesis], Erasmus University Rotterdam, 1999.
31. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psych Meas 1977;1:385-401.
32. Beekman AT, Deeg DJ, Van Limbeek J, Braam AW, De Vries MZ, Van Tilburg W. Criterion validity of the Center for Epidemiologic Studies Depression scale (CES-D): results from a community-based sample of older subjects in The Netherlands. Psychol Med 1997;27:231-5.
33. Gardiner JC, Luo Z, Roman LA. Fixed effects, random effects and GEE: what are the differences? Stat Med 2009;28:221-39.
34. Hubbard AE, Ahern J, Fleischer NL, et al. To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. Epidemiology 2010;21:467-74.
35. Murata Y, Kamishioiri Y, Tanaka K, et al. Severe sleepiness and excess sleep duration induced by paroxetine treatment is a benefcial pharmacological effect, not an adverse reaction. J Affect Disord 2013;150:1209-12.
36. Gardarsdottir H, Heerdink ER, van Dijk L, Egberts AC. Indications for antidepressant drug prescribing in general practice in the Netherlands. J Affect Disord 2007;98;109-15.
37. Noordam R, Aarts N, Verhamme KM, Sturkenboom MC, Stricker BH, Visser LE. Prescription and indication trends of antidepressant drugs in the Netherlands between 1996 and 2012: a dynamic population-based study. Eur J Clin Pharmacol 2015;71:369-75.